Actively Recruiting
Feasibility of Hyivy Device Post-Radiation for Pelvic Malignancies
Led by Hyivy Health Inc · Updated on 2025-04-22
12
Participants Needed
1
Research Sites
59 weeks
Total Duration
On this page
Sponsors
H
Hyivy Health Inc
Lead Sponsor
G
Grand River Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Vaginal dilator therapy (VDT) with static dilators is often prescribed to patients following vaginal or pelvic radiation therapy. This study seeks to evaluate the feasibility of a novel intravaginal device that delivers patient-controlled dilation (Hyivy device). The study is designed as a proof-of-concept single-arm pilot study. The primary objective is to assess safety and tolerability, while also evaluating changes in health-related quality of life and pelvic pain.
CONDITIONS
Official Title
Feasibility of Hyivy Device Post-Radiation for Pelvic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of enrollment
- Have a vagina or vaginal canal and completed radiation therapy (external beam or brachytherapy) for endometrial, cervical, anal, or rectal cancer without chemotherapy
- Generally in good health apart from cancer, as determined by the investigator
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
- Post-menopausal for at least 1 year or surgically sterile, or child-bearing potential participants must use approved birth control during the study, with hormonal birth control used for at least 3 months
- Agree not to use other vaginal dilators during the 12-week intervention
- Ability to charge the investigational device
- Willing and able to insert the intravaginal device
- Able to understand, comply with, and consent to study requirements
- Able to attend scheduled visits and complete required tests
- Willing and able to sign written informed consent
You will not qualify if you...
- Pregnant or planning pregnancy during the trial
- Major surgery in past 3 months unless post-surgery dilator use is recommended or planned major surgery during the study
- Any medical condition or finding that contraindicates device use or may affect results, as judged by investigator
- Allergy to Hyivy device materials
- Active pelvic or gynecological infection
- Current antibiotic use for infection
- Open wounds, cuts, or sores in vaginal or pelvic area
- Severe atrophic vaginitis or very dry, itchy, or sore vaginal area, per investigator discretion
- Loss of pelvic floor sensation (hypoesthesia)
- Total or partial prolapse of uterus or vagina
- Severe urinary retention, severe extra-urethral incontinence, or overflow incontinence
- Unable to position the device properly
- Use of medical devices that could interfere with the investigational device, like pacemakers, ventilators, or ear implants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Grand River Regional Cancer Centre, Waterloo Regional Health Network @ Midtown
Kitchener, Ontario, Canada, N2G 1G3
Actively Recruiting
Research Team
D
Daniel Glick, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here